oasis 1 oral semaglutide 50 mg obesity lancet 2023 Most viewed this week from JAMA Internal Medicine: of # daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or # Oral semaglutide: an OASIS from

doi: 10.3389/fphar.2025.1638527 Received 30 May 2025 Accepted 16 July 2025 Published 05 August 2025 Volume 16 - 2025 Edited by Di Yuan, Xidian University, China Reviewed by Asmaa ShamsEldeen, Cairo University, Egypt Jinmei Tuo, Zunyi Medical University, China Rao Chaolong, Chengdu University of Traditional Chinese Medicine, China Updates Copyright 2025 Alolayan and Alhowail

Safety Profile: What We Learned About Side Effects Common Adverse Events The TRIUMPH-4 trial confirmed that retatrutide's side effect profile aligns with other incretin-based therapies, with gastrointestinal symptoms being the most common: Incidence of GI Side Effects (12mg dose): Nausea: 43% (vs 11% placebo) Diarrhea: 33% (vs 13% placebo) Vomiting: 21% (vs 0% placebo) Constipation: Elevated vs placebo Decreased appetite: Common Most gastrointestinal side effects were mild to moderate in severity and occurred primarily during the dose escalation phase

Compounding allows PlexusDx to offer customized formulationsinjection or oraltailored to individual needs without requiring prior insurance denials

THE STEM CELL PDRN & GLUTATHIONE PURE ESSENCE , , ,

One of DSIP most interesting properties is its apparent safety profile

Semaglutide & weight health Expectations, side effects, and lifestyle support